Last updated on November 2017

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD


Brief description of study

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

Detailed Study Description

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01371981?term=AAML1031&rank=1

Clinical Study Identifier: TX2024

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Patricia Green

Memorial University Medical Center
Savannah, GA USA
  Connect »